论文部分内容阅读
本文叙述了临床试用的几种免疫避孕方法近年来的发展概况。ｈＣＧ疫苗主要有两种形式：整个βｈＣＧ疫苗及βｈＣＧ－ＣＴＰ疫苗。初步临床试验表明，这两种形式疫苗是安全的，但仍然存在着低免疫原性、生物效应差以及不同的个体反应性问题。βｈＣＧ免疫原性虽比βｈＣＧ－ＣＴＰ强，但βｈＣＧ与ｈＬＨ交叉免疫问题尚未解决，因此ＷＨＯ目前仅支持βｈＣ－ＧＣＴＰ疫苗的发展。ＧｎＲＨ疫苗可用于男性避孕，但还需睾酮替代治疗；亦可用于产后妇女，以延长哺乳期妇女的不排卵期。ＦＳＨ疫苗目前已进人Ⅰ期临床试验，是第一个试用于男性的避孕疫苗，可使受试者发生少精或无精症，从而发生不育。另外，楝树油可激发局部细胞介导的免疫反应，诱发细胞因子，转而杀死精子或胚胎，造成不育。
This article describes the clinical trials of several methods of immunization contraception in recent years, the development of an overview. The hCG vaccine has two major forms: the entire βhCG vaccine and the βhCG-CTP vaccine. Preliminary clinical trials have shown that both forms of vaccines are safe, but low immunogenicity, poor biological effects, and varying individual reactivity problems remain. Although the immunogenicity of βhCG is stronger than that of βhCG-CTP, the cross-immunization of βhCG with hLH remains unresolved. Therefore, WHO currently only supports the development of βhC-GCTP vaccine. GnRH vaccine can be used for male contraception, but also need testosterone replacement therapy; also be used for postpartum women to prolong the anovulatory period of lactating women. The FSH vaccine has now entered Phase I clinical trials and is the first contraceptive vaccine to be tested in men, resulting in infertility with less or no azoospermia in the subject. In addition, Neem oil can stimulate local cell-mediated immune response, induce cytokines, which in turn kill sperm or embryos, resulting in infertility.